Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN has launched QIAseq Targeted cfDNA Ultra Panels, enabling researchers to convert cell-free DNA (cfDNA) liquid biopsy samples into libraries for next-generation sequencing (NGS) within eight hours. This innovation enhances the detection of somatic mutations in low-concentration cfDNA, vital for cancer diagnosis and monitoring.
The panels will be showcased at the AACR 2023 conference and can detect variants as low as 0.1% variant allele frequency. Additionally, QIAGEN will introduce new pan-cancer panels for its QIAcuity digital PCR platform in fall 2023, designed for efficient analysis of important cancer-related genes.
QIAGEN aims to improve cancer research and patient outcomes with these advancements, including precise mutation detection and streamlined workflows, enhancing laboratory productivity.
QIAGEN N.V. (NYSE: QGEN) has filed its annual report on Form 20-F for the year ending December 31, 2022, with the U.S. Securities and Exchange Commission. The report is available for access on QIAGEN’s website. The company provides free printed copies of the annual report to shareholders upon request. QIAGEN is a leading provider of Sample to Insight solutions, offering technologies for isolating and processing biomolecules. As of December 31, 2022, the company employed approximately 6,200 people globally, serving over 500,000 customers across various sectors such as molecular diagnostics and academia.
QIAGEN has partnered with Servier to develop a PCR test for detecting isocitrate dehydrogenase-1 (IDH1) mutations in acute myeloid leukemia (AML) patients. This companion diagnostic will be utilized with Servier’s TIBSOVO®, an IDH1 inhibitor treatment. The test will run on QIAGEN's Rotor-Gene Q device, targeting blood and bone marrow samples. QIAGEN, a leader in companion diagnostics, collaborates with over 30 companies to advance precision medicine. The collaboration aims to enhance patient access to targeted treatments for the 6-10% of AML patients with IDH1 mutations, showcasing QIAGEN's commitment to innovation in oncology diagnostics.
QIAGEN N.V. (NYSE: QGEN) has launched the QIAseq Platform Partnership with SOPHiA GENETICS (NASDAQ: SOPH), aimed at improving the compatibility of QIAGEN's NGS kits with digital data-sharing platforms. This collaboration will enable somatic variant detection using QIAseq panels for homologous recombination repair, enhancing research in precision diagnostics. The partnership is set to expand to custom solutions, allowing greater access to data-driven medicine. Notably, QIAGEN has processed about four million samples with their NGS panels, solidifying their position in the genomics market.
SOPHiA GENETICS (Nasdaq: SOPH) has entered into a partnership with QIAGEN (NYSE: QGEN) to integrate QIAseq reagent technology with its SOPHiA DDM™ platform. This collaboration aims to enhance tumor analysis through next-generation sequencing (NGS), specifically supporting somatic variant detection related to homologous recombination repair. The partnership allows customers to access QIAseq panels for improved data analysis, enhancing research capabilities in oncology. Both companies are optimistic about the positive impact on medicine and research.
QIAGEN has announced the certification of its QuantiFERON-TB Gold Plus test under the new EU In Vitro Diagnostic Medical Devices Regulation (IVDR), classified as Class C. This certification marks a key milestone in QIAGEN's compliance with EU regulations aimed at enhancing diagnostic performance and safety. The QuantiFERON-TB Gold Plus test is recognized globally, including by WHO, for its effectiveness in detecting tuberculosis. As part of its commitment, QIAGEN is transitioning over 180 products to meet the IVDR standards, ensuring continued supply and compliance moving forward.
QIAGEN N.V. (NYSE: QGEN) reported Q4 2022 net sales of
QIAGEN has launched the EZ2 Connect MDx platform for diagnostic laboratories, enhancing sample processing capabilities 18 months after its research introduction. This automated device purifies DNA and RNA from 24 samples in approximately 30 minutes and is CE-IVD compliant, enabling its use across the EU, U.S., Canada, and more. With over 5,000 EZ platforms deployed globally, EZ2 Connect MDx integrates with the QIAsphere digital system for remote management, meeting the fast-paced demands of clinical diagnostics. It addresses various sample types, employing magnetic-bead technology and ensuring high process safety.
FAQ
What is the current stock price of QIAGEN N.V. (QGEN)?
What is the market cap of QIAGEN N.V. (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
